ESR1 and breast carcinoma: Indeed, convincing evidence has demonstrated that use of epigenetic modulators, such as DNA methyltransferase (DNMT) inhibitors [12] and histone deacetylase (HDAC) inhibitors [13,14], in cancer treatment successfully re−expressed ER−α and enhanced sensitivity to endocrine therapy in ER−α−negative breast cancers.